Market Pulse: Immunogen expands clinical testing for a cancer drug
7th Sep 2005, 16:23 GMT
ImmunoGen a Cambridge, Mass., developer of anti-cancer drugs, said it would conduct clinical testing with its Tumor-Activated Prodrug compound, huN901-DM1, to treat multiple myeloma.
Latest news from Operations-Related News from myHealthcareNews.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies